Shopping Cart
- Remove All
- Your shopping cart is currently empty
Teclistamab (JNJ-64007957) is a human bispecific monoclonal antibody targeting the CD3 receptor expressed on the surface of t-cells and the b-cell maturation antigen (BCMA) expressed on the surface of malignant multiple myeloma b-lineage cells for the treatment of relapsed and refractory multiple myeloma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $689 | In Stock | |
5 mg | $1,590 | In Stock | |
10 mg | $2,180 | In Stock | |
25 mg | $3,230 | In Stock | |
50 mg | $4,370 | 8-10 weeks | |
100 mg | $5,890 | 8-10 weeks |
Description | Teclistamab (JNJ-64007957) is a human bispecific monoclonal antibody targeting the CD3 receptor expressed on the surface of t-cells and the b-cell maturation antigen (BCMA) expressed on the surface of malignant multiple myeloma b-lineage cells for the treatment of relapsed and refractory multiple myeloma. |
In vitro | Methods: Frozen BM MNCs were treated with Teclistamab (0-532 nM) with or without exogenous healthy T cells to measure target engagement and killing. Results: Teclistamab-induced cytotoxicity in BM MNCs had comparable EC50s (1.5-4.2 nM) in all 3 patient samples; Teclistamab-mediated T cell activation was also similar in all BM MNC samples with EC50s (0.93 - 1.75 nM). [1] |
Alias | JNJ-64007957, JNJ64007957 |
Cas No. | 2119595-80-9 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.